DOCSLIB.ORG

Approved Drug List 2019, March

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Approved Drug List 2019, March c Maldives Food and Drug Authority Ministry of Health Male’, Republic of Maldives Approved Drug List Number: MTG/RE-AL/Li 0009/2019-0003 Acronym Expansion Remarks R Registered product These are pharmaceutical products registered and approved with full dossier submission. Product safety, quality and efficacy has been evaluated based on the submitted documents and certificates of the manufacture and the product Once registered and approved, it is the Re Registered product which has responsibility of the marketing authorization holder to been given exclusivity under set provide all necessary information required and if there is condition. any change in the product/packaging etc., and to ensure that the product is available in the market. EA Exemption Approvals These are special approvals for importing pharmaceutical products based on minimum evaluation of safety and quality of the product with information of the imports and availability in the market of the same. This approval is a temporary approval granted for a period of 1 year. For further import after 1 year, it has to be registered by full dossier submission under the registration criteria. Once registered by submitting full dossier then it will be added to the registered product list. TA Temporary Approvals These are the Products approved based on physicians requisition forms submitted by clinicians, and these products are in generic name and Pre Authorization has to be taken prior to import.These products will be kept as approved products for a period of 1 year , and as pre authorization required products. If needed for further import it has to be registered by full dossier submission under the registeration criteria. PP Primordial Products These are the products that has been in Approved Drug List from the beginning as approved products but not registered with full dossier submission. This has been kept in the Approved Drug List due to the unavailability of any alternative, plus that these products are kept on the fact that it has been in the market for a long time. Pre Authorization For all those products These are in generics and it is mentioned that Pre required products (PA) highlighted in Green Authorization has to be taken prior to import. Pre- authorization is an approval taken to import these products and it has to be taken for each product and for every shipment for import. MTG Division, MFDA Rec. Name: Approved Drug List Rec. No.: MTG/RE-AL/Li 0009 Issued Date: 12/02/2018 Issue No.: 02 Rev.Date: 19.02.2019 Rev. No.: 02 Page 1 of 2 Authorized by:DG,MFDA Restricted for Hospital Medicines restricted to special These are the medicines that can only be imported by and institutional use only expertise and Health facilties designated parties.These products cannot be kept for sale in (HI) and clinics with registered pharmacies. medical practitioners Restricted for Hospital Medicine restricted to special These are the medicines that can only be imported by use only (HO) expertise for hospitals only designated parties.These products cannot be kept for sale in pharmacies. Restricted for the Restricted to Use for the These medicines can only be imported to be used by the National programs only National programes only (eg. National Programes based on a valid request by the (NP) Filaria, Leprosy, Malaria, concerned agency TB,HIV,EPI, Reproductive Health Programs etc) CONTROLLED ( C ) Controlled Drugs which include These are medicines which are controlled and can only be Narcotics and Psychotropics imported by designated parties.From these medicines (Internationally and Nationally Narcotics cannot be kept in pharmacies for sale Controlled). OTC Over the counter medicine (OTC) These are the medicines that can be sold without prescriptions POM Prescription only medicine (POM) These are medicines that can be sold to a valid prescription only. E Essential medicine These are medicines that are essential and is in the most recent National Essential medicine list Updated on: 3rd March 2019 Color codes Category Text/Highlighted Colour Explanation Prescription Only Black All the "POM" drugs are in black text Medicine (POM) Over the Counter (OTC) Blue All the "OTC" drugs are in blue text CONTROLLED Purple All the "Controlled" medicine are in purple text Restricted for Hospital Dark Blue All the "Restricted for Hospital use only & Restricted use only & Restricted for Hospital use/institutional use only" medicines for Hospital are in dark blue text use/institutional use only Restricted and to be Dark Red All the "Restricted and to be used for the National used for the National program only" medicines are in dark red text program only Pre-Authorization required before import All the "Pre-Authorization required before import" items are highlighted in light green Products proposed to be removed after evaluation "Products proposed to be removed after evaluation" are highlighted in red colour 1. For the Products in this list where the formulation is mentioned, that specific formulation only can be imported 2. For those products in which the fomulation is not mentioned, the product imported should be of export quality and not specified for a specific market MTG Division, MFDA Rec. Name: Approved Drug List Rec. No.: MTG/RE-AL/Li 0009 Issued Date: 12/02/2018 Issue No.: 02 Rev.Date: 19.02.2019 Rev. No.: 02 Page 2 of 2 Authorized by:DG,MFDA List 1: Registered Product List These are pharmaceutical products registered and approved with full dossier submission. Product safety, quality and efficacy has been evaluated based on the submitted documents and certificates of the manufacture and the product Once registered and approved, it is the responsibility of the marketing authorization holder to provide all necessary information required and if there is any change in the product/packaging etc., and to ensure that the product is available in the market. Product Generic name Product name Manufacturer / Company Dosage form Strength Catergory Status Registered Remarks No name Date Serial No. Essentiality 1 P2123 ACARBOSE BP Glucar - 50 Glenmark Pharmaceuticals Tablet 50 mg POM R E Ltd., India 2 P2423 ACECLOFENAC Aceclo Aristo India Tablet 100 mg POM R 25.10.2010 Registered by ADK Company Pvt Ltd 3 P3678 ACECLOFENAC BP Acelodon 100 Swiss Garnier Life Sciences, Tablet 100 mg POM Re 01.03.2016- Market Exclusivity No. 21-23, Industrial Area, 28.02.2021 given to AMDC Pvt. Mehatpur, Dist: UNA, (H.P.)- Ltd. 174 315, India 4 P2716 ACECLOFENAC BP Acedol Torrent Pharmaceuticals, Tablet 100 mg POM R 19.02.2013 Registered by Life India Support Pvt Ltd 5 P2275 ACECLOFENAC BP Acenac Medley Pharmaceuticals Ltd, Tablet 100 mg POM R Registered by ADK India. Company Pvt Ltd 6 P3140 ACECLOFENAC BP Aeronac Cassel Research Laboratories, Tablet 100 mg POM R 19.08.2014 Registered by My India Chemist Wholesale 7 P3508 ACECLOFENAC BP Acenac-SR Medley Pharmaceuticals Ltd, Sustained Release 200 mg POM Re 19.05.2015- Market Exclusivity India. Tablet 18.05.2020 given to ADK Company Pvt. Ltd. 8 P3267 ACECLOFENAC BP + LINSEED OIL BP + Stednac Stedman Pharmaceuticals Gel 1.5% w/w + 3.0% + 10% + 5% POM R 06.01.2015 Registered by AMDC METHYL SALICYLATE BP + MENTHOL GEL Pvt. Ltd., India Pvt Ltd USP 9 P2427 ACETYL SALICYLIC ACID Delisprin 75 Aristo India Tablet (Delayed 75 mg POM R E 25.10.2010 Registered by ADK Release) Company Pvt Ltd 10 P3932 ACETYL SALICYLIC ACID (ASPIRIN) Casprin Y.S.P. Industries (M) Sdn. Enteric Micro- 100 mg POM Re E 01.11.2016 - Market Exclusivity Bhd. Lot 3, 5 & 7, Jalan P/7, encaptulated 31.10.2021 given to Treetop Section 13, Kawasan Capsule Health Pvt. Ltd. Perindustrian Bandar Baru bangi, 43000 Kajang, Selangor Darul Ehsan, Malaysia MTG Division, MFDA Rec. Name: Approved Drug List Rec. No.: MTG/RE-AL/Li 0009 Issued Date: 12/02/2018 Issue No.: 02 Rev.Date: 19.02.2019 Rev. No.: 02 Page 1 of 111 Authorized by:DG,MFDA 11 P4329 ACICLOVIR / ACYCLOVIR BP Virox SM Pharmaceuticals Sdn. Tablet 200mg POM Re E 02.10.2018 - Market Exclusivity Bhd. Lot 88, Sungai Petani 01.10.2023 given to Green Industrial Estate, 08000 Pharmacy Godown Sungai Petani, Kedah, Malaysia 12 P4330 ACICLOVIR / ACYCLOVIR BP Virox SM Pharmaceuticals Sdn. Tablet 400mg POM Re E 02.10.2018 - Market Exclusivity Bhd. Lot 88, Sungai Petani 01.10.2023 given to Green Industrial Estate, 08000 Pharmacy Godown Sungai Petani, Kedah, Malaysia 13 P2611 ACICLOVIR/ ACYCLOVIR Virest Hovid Bhd, Malaysia Cream 5% POM R E 10.07.2012 Registered by GKT Pharmacy 14 P2185 ACICLOVIR/ ACYCLOVIR Herperax 200 Micro Labs ltd., India Tablet 200 mg POM R E Registered by ADK Company Pvt Ltd 15 P2607 ACICLOVIR/ ACYCLOVIR Virest Hovid Bhd, Malaysia Tablet 400 mg POM R E 10.07.2012 Registered by GKT Pharmacy 16 P2608 ACICLOVIR/ ACYCLOVIR Virest Hovid Bhd, Malaysia Tablet 200 mg POM R E 10.07.2012 Registered by GKT Pharmacy 17 P2804 ACICLOVIR/ ACYCLOVIR Zovirax GlaxoSmithKline , Spain Tablet 200 mg POM R E 26.08.2013 Registered by ADK Company Pvt Ltd 18 P2805 ACICLOVIR/ ACYCLOVIR Zovirax GlaxoSmithKline , Spain Tablet 800 mg POM R E 26.08.2013 Registered by ADK Company Pvt Ltd 19 P2203 ACICLOVIR/ ACYCLOVIR Herperax Micro Labs ltd Ointment 5% POM R E Registered by ADK Company Pvt Ltd 20 P3214 ACICLOVIR/ ACYCLOVIR Zovirax Glaxo Operations, UK Cream 5% w/w POM R E 06.11.2014 Registerd by State Trading Organization Plc. 21 P606 ACICLOVIR/ ACYCLOVIR Zovirax GlaxoSmithKline Injection 250mg/vial POM R E 06.11.2014 Registerd by State Manufacturing S.p.A, Italy Trading Organization Plc. 22 P1832 ACICLOVIR/ ACYCLOVIR Declovir cream HOE Pharmaceutical Cream 5.00% POM R E Manufacturing (M) Sdn. Bhd., Malaysia 23 P1974 ACICLOVIR/ ACYCLOVIR Virux Square Formulations Tablet 200 mg POM R E Ltd.
Load more

Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000
    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
    [Show full text]
  • Dorset Medicines Advisory Group
    DORSET CARDIOLOGY WORKING GROUP GUIDELINE FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION SUMMARY The pan-Dorset cardiology working group continues to recommend the use of amlodipine (a third generation dihydropyridine calcium-channel blocker) as first choice calcium channel blocker on the pan-Dorset formulary for hypertension. Lercanidipine is second choice, lacidipine third choice and felodipine is fourth choice. This is due to preferable side effect profiles in terms of ankle oedema and relative costs of the preparations. Note: where angina is the primary indication or is a co-morbidity prescribers must check against the specific product characteristics (SPC) for an individual drug to confirm this is a licensed indication. N.B. Lacidipine and lercandipine are only licensed for use in hypertension. Chapter 02.06.02 CCBs section of the Formulary has undergone an evidence-based review. A comprehensive literature search was carried out on NHS Evidence, Medline, EMBASE, Cochrane Database, and UK Duets. This was for recent reviews or meta-analyses on calcium channel blockers from 2009 onwards (comparative efficacy and side effects) and randomised controlled trials (RCTs). REVIEW BACKGROUND Very little good quality evidence exists. No reviews, meta-analyses or RCTs were found covering all calcium channel blockers currently on the formulary. Another limitation was difficulty obtaining full text original papers for some of the references therefore having to use those from more obscure journals instead. Some discrepancies exist between classification of generations of dihydropyridine CCBs, depending upon the year of publication of the reference/authors’ interpretation. Dihydropyridine (DHP) CCBs tend to be more potent vasodilators than non-dihydropyridine (non-DHP) CCBs (diltiazem, verapamil), but the latter have greater inotropic effects.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • PMBJP Product.Pdf
    Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (OTC) Antibiotics in the European Union and Norway, 2012
    Perspective Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012 L Both 1 , R Botgros 2 , M Cavaleri 2 1. Public Health England (PHE), London, United Kingdom 2. Anti-infectives and Vaccines Office, European Medicines Agency (EMA), London, United Kingdom Correspondence: Marco Cavaleri ([email protected]) Citation style for this article: Both L, Botgros R, Cavaleri M. Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012. Euro Surveill. 2015;20(34):pii=30002. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2015.20.34.30002 Article submitted on 16 September 2014 / accepted on 09 February 2015 / published on 27 August 2015 Antimicrobial resistance is recognised as a growing throughout the EU; however, there are still consider- problem that seriously threatens public health and able differences in Europe due to the different health- requires prompt action. Concerns have therefore been care structures and policies (including the extent of raised about the potential harmful effects of making pharmacist supervision for OTC medicines), reimburse- antibiotics available without prescription. Because of ment policies, and cultural differences of each Member the very serious concerns regarding further spread of State. Therefore, the availability of OTC medicines var- resistance, the over-the-counter (OTC) availability of ies in the EU and products sold as POM in certain coun- antibiotics was analysed here. Topical and systemic tries can be obtained as OTC medicines in others. OTC antibiotics and their indications were determined across 26 European Union (EU) countries and Norway As risk minimisation is an important criterion for some by means of a European survey.
    [Show full text]
  • FIXED DOSE COMBINATIONS APPROVED by DCG (I) SINCE 1961 TILL 22Nd February 2019
    FIXED DOSE COMBINATIONS APPROVED BY DCG (I) SINCE 1961 TILL 22nd February 2019 # Name of Drug Indication Date of approval 1. Cyanocobalamine + Zinc tannic acid complex Jan-61 2. Cobalt glutamate + Copper Glycinate Aug-61 3. Fibrinolysin + Desoxyribonuclease Feb-62 4. Tablets of Norethisterone acetate + Ethinyl Nov-62 oestradiol 5. Tablets of Norethynodrel and Ethinyl Estradiol 3-methyl ether Dec-62 6. Broxyquinoline + Brobenzoxalidine May-63 7. Testosterone decanoate + Isocaproate Jan-64 8. Combination of L Oxethazaine + Aluminium hydroxide + Magnesium Hydroxide Jun-66 9. Amylobarbitone + Trifluperazine Dihydrochloride Capsule Feb-67 10. Lynestronol 2.5mg + Mestranol 0.075mg Tablet Apr-67 11. Northynodrel 2.5mg + Mestranol 0.1mg Jun-67 12. Norethisterone 2mg and Mestranol 0.1mg May-67 13. Mestranol 4mg + Ethinyloestradial 0.05mg May-67 Tablet 14. Norethisterane acetate + ethinyl estradiol May-67 15. Aluminium sodium silicate + Magnesium hydroxide + Methypolysiloxane Tablet Jun-67 16. Ammoidin + Amidine Jul-67 17. Fluocortolene + Flucortolene Caproate Jul-68 18. Norgestrel + Ethinyloestradiol Tablet Aug-68 19. Folic Acid 0.5mg + Ferrous Sulphate 150mg Jan-69 Capsule 20. Tetracycline HCl 250mg + Broxyquinoline 200mg + Brobenzoxadine 40mg Jan-69 21. Methyldopa 250mg + HCTZ 15mg Tablet Feb-69 22. dl Norgestrel + 17 alpha hydroxy progesterone caproate + Norethisterone acetate + 17 alpha Jan-69 acetoxy progesterone 23. Diphenoxylate HCl 2.5mg + Atropine Sulphate 0.025mg tablet Jul-69 24. Vitamin A,D & E Jul-69 25. Lutin 0.1gm + Vit 0.1gm + Vit K1 2.5mg + Dicalcium Phosphate 0.1gm + Carlozochrome Jul-69 Salicylate 1mg tablet 26. Vit K 1 5mg + Calcium Lactolionate 100 m g+ Carlozocrome Salicylate 2.5mg + Phenol 0.5% Jul-69 + Lignocaine Hcl 1% injection 27.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0220837 A1 Disegi Et Al
    US 2005O220837A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0220837 A1 Disegi et al. (43) Pub. Date: Oct. 6, 2005 (54) ANTIMICROBIAL HYALURONIC ACID Related U.S. Application Data COATINGS FOR ORTHOPEDIC IMPLANTS (60) Provisional application No. 60/506,760, filed on Sep. (76) Inventors: John Arthur Disegi, Reading, PA (US); 30, 2003. Robert Geoffrey Richards, Davos Dorf (CH); Llinos Gwawr Harris, Davos Publication Classification Platz (CH) (51) Int. Cl. .............................. A61F 2/28: A61F 13/00 Correspondence Address: (52) U.S. Cl. ......................................... 424/423; 623/16.11 JONES DAY 222 EAST 41ST ST NEW YORK, NY 10017 (US) (57) ABSTRACT (21)21) AppAppl. No.: 10/955,7771955, The invention relates to an implantp wherein the Surface of the implant is coated with hyaluronic acid or a derivative (22) Filed: Sep. 30, 2004 thereof. The coated implants resist microbial growth. Patent Application Publication Oct. 6, 2005 Sheet 1 of 5 US 2005/0220837 A1 FIGURE 1A FIGURE 1B FIGURE 1G TSS THY TG TF TAST FIGURE 1D FIGURE 1E FIGURE 1F FIGURE 2A FIGURE 2B Patent Application Publication Oct. 6, 2005 Sheet 2 of 5 US 2005/0220837 A1 TS TC FIGURE 3A FIGURE 3B FIGURE 4A FIGURE 4B CAC - 48 hours CP - 48 hours CPC - 48 hours FIGURE 4C FIGURE 4D Patent Application Publication Oct. 6, 2005 Sheet 3 of 5 US 2005/0220837 A1 FIGURE 5A FIGURE SB CP - 48 hours CP-96 hours FIGURE 5C FIGURE 5D FIGURE 6A FIGURE 6B CAC-96 hours - CPC-96 hours FIGURE 6C FIGURE 6D Patent Application Publication Oct.
    [Show full text]
  • Selection of Effective Cocrystals Former for Dissolution Rate Improvement Of
    Selection of effective cocrystals former for dissolution rate improvement of active pharmaceutical ingredients based on lipoaffinity index Piotr Cysewski, Maciej Przybylek To cite this version: Piotr Cysewski, Maciej Przybylek. Selection of effective cocrystals former for dissolution rate im- provement of active pharmaceutical ingredients based on lipoaffinity index. European Journal of Pharmaceutical Sciences, Elsevier, 2017, 107, pp.87-96. 10.1016/j.ejps.2017.07.004. hal-01773096 HAL Id: hal-01773096 https://hal.archives-ouvertes.fr/hal-01773096 Submitted on 29 Apr 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Accepted Manuscript Selection of effective cocrystals former for dissolution rate improvement of active pharmaceutical ingredients based on lipoaffinity index Piotr Cysewski, Maciej Przybyłek PII: S0928-0987(17)30403-7 DOI: doi: 10.1016/j.ejps.2017.07.004 Reference: PHASCI 4127 To appear in: European Journal of Pharmaceutical Sciences Received date: 11 April 2017 Revised date: 6 June 2017 Accepted date: 3 July 2017 Please cite this article as: Piotr Cysewski, Maciej Przybyłek , Selection of effective cocrystals former for dissolution rate improvement of active pharmaceutical ingredients based on lipoaffinity index, European Journal of Pharmaceutical Sciences (2017), doi: 10.1016/j.ejps.2017.07.004 This is a PDF file of an unedited manuscript that has been accepted for publication.
    [Show full text]
  • Cilnidipine, but Not Amlodipine, Ameliorates Osteoporosis in Ovariectomized Hypertensive Rats Through Inhibition of the N-Type Calcium Channel
    Hypertension Research (2012) 35, 77–81 & 2012 The Japanese Society of Hypertension All rights reserved 0916-9636/12 www.nature.com/hr ORIGINAL ARTICLE Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel Hideo Shimizu1, Hironori Nakagami2, Natsuki Yasumasa2, Osako Kiomy Mariana3, Mariko Kyutoku3, Hiroshi Koriyama3, Futoshi Nakagami3, Munehisa Shimamura2, Hiromi Rakugi1 and Ryuichi Morishita3 Both osteoporosis and high blood pressure are major diseases in aging populations. Recent studies demonstrated that some antihypertensive drugs reduced the risk of bone fracture in elderly patients. Although calcium channel blockers (CCB) are widely used as first-line antihypertensive agents, there is no evidence that they prevent osteoporosis. In this study, we investigated the effects of two types of CCB on bone metabolism: cilnidipine (L-/N-type CCB), which suppresses norepinephrine release from the sympathetic nerve, and amlodipine (L-type CCB). In ovariectomized female spontaneous hypertensive rats, administration of cilnidipine, but not amlodipine, resulted in a significant increase in the ratio of alkaline phosphatase to tartrate-resistant acid phosphatase (TRAP) and a decrease in the number of osteoclasts, as assessed by TRAP staining in the proximal tibia. Bone mineral density, moreover, was significantly higher in the cilnidipine group as compared with the amlodipine group and was associated with a significant decrease in a urinary collagen degradation product (deoxypyridinoline). The degree of prevention of osteoporosis by cilnidipine was similar to that of carvedilol (a b-blocker) because b-blockers reduce fracture risks though the inhibition of osteoclast activation. Interestingly, these effects cannot be attributed to the reduction of blood pressure because all three drugs significantly decreased blood pressure.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]